August 6, 2026

FDA Approves First mRNA-Based Flu Vaccine

The mFLUSIVA vaccine is designed for individuals over 50, who face the highest flu-related risks.
This mRNA technology allows for faster production and adaptation to flu strains.
The vaccine's approval comes after a controversial funding cut by Health Secretary Robert F. Kennedy Jr. for mRNA research.

Read the news this way every day.

Concur organizes political reporting into clear stories and shows the sources behind each one.

Free. No ads.